Who Owns Arcutis Biotherapeutics Stock?
NASDAQ: ARQTHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Ownership breakdown
- Held by institutions
- 108.74%
- Institutions (% of float)
- 110.69%
- Held by insiders
- 1.77%
- Institutional holders
- 391
- Institutions 98.2%
- Insiders 1.8%
- Public and other 0.0%
Who owns Arcutis Biotherapeutics stock?
Institutional investors own about 108.7% of Arcutis Biotherapeutics's shares, spread across 391 institutions that file 13F reports. That level of institutional ownership is high, typical of large, widely followed companies. Insiders, including executives, directors and large founding shareholders, hold 1.77% of ARQT.
The largest institutional holders are Montanova Capital LLC (9.89%), Blackrock Inc. (8.39%) and Frazier Life Sciences Management, L.P. (7.86%). Together, the top 10 institutions control 56.6% of shares outstanding. In their latest filings, 6 of the top 10 institutions increased their ARQT positions and 2 reduced them.
Summary generated from market data by MetaCap's automated system. Methodology
Top institutional holders of ARQT
| Institution | Shares | % Held | Change |
|---|---|---|---|
| Montanova Capital LLC | 12.44M | 9.89% | +0.9% |
| Blackrock Inc. | 10.55M | 8.39% | +14.6% |
| Frazier Life Sciences Management, L.P. | 9.87M | 7.86% | 0.0% |
| Rubric Capital Management LP | 8.27M | 6.58% | 0.0% |
| Polar Capital Holdings PLC | 6.61M | 5.26% | +16.6% |
| State Street Corporation | 5.82M | 4.63% | -7.5% |
| Vanguard Capital Management LLC | 4.99M | 3.97% | +2.4% |
| Morgan Stanley | 4.45M | 3.54% | +5.5% |
| Jennison Associates LLC | 4.22M | 3.36% | -15.3% |
| Shaw D.E. & Co., Inc. | 3.95M | 3.14% | +58.2% |
% held is the share of total shares outstanding. Change is the percentage change in the position since the holder's previous 13F filing.
Top mutual fund and ETF holders of ARQT
| Fund | Shares | % Held |
|---|---|---|
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 3.56M | 2.84% |
| SPDR SERIES TRUST-State Street SPDR S&P Biotech ETF | 3.07M | 2.44% |
| iShares Trust-iShares Russell 2000 ETF | 2.90M | 2.31% |
| American Century Mutual Funds, Inc.-Small Cap Growth Fund | 1.47M | 1.17% |
| Prudential Jennison Small Co Fd., Inc.-PGIM JENNISON SMALL COMPANY Fd. | 1.39M | 1.10% |
| VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund | 1.31M | 1.04% |
| Fidelity Salem Street Trust-Fidelity Small Cap Index Fund | 1.25M | 0.99% |
| OBERWEIS FUNDS-Oberweis Small-Cap Opportunities Fund | 1.21M | 0.96% |
| iShares Trust-iShares Russell 2000 Growth ETF | 1.07M | 0.85% |
| BARON INVESTMENT Fd.S TRT -BARON DISCOVERY Fd. | 867.40K | 0.69% |
Frequently asked questions
Who is the largest shareholder of Arcutis Biotherapeutics?
Montanova Capital LLC is the largest institutional shareholder of ARQT, owning 9.89% of shares outstanding (12.44M shares) as of its latest 13F filing.
What percentage of Arcutis Biotherapeutics is owned by institutions?
Institutions own about 108.7% of ARQT shares and 110.7% of the public float.
How much of Arcutis Biotherapeutics do insiders own?
Insiders, such as officers and directors, own about 1.77% of ARQT shares outstanding.
Where does institutional ownership data come from?
Investment managers with more than $100 million in US equities must file Form 13F with the SEC within 45 days of each quarter-end. Holdings are therefore up to about 4.5 months old when published.